Clinical Trial Update: MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of MEM-288 oncolytic virus in advanced solid tumors, evaluating MEM-288 alone and in combination with standard-of-care therapy. The trial is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Head and Neck Cancer
• Melanoma
• Merkel Cell Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• MEM-288

Snippet

Sponsor: Memgen, Inc. | Conditions: Solid Tumor, Advanced Cancer | Phase 1 | Status: RECRUITING